India–Russia Cooperation for Building an Independent Pharmaceutical Supply Chain
Pharmaceutical cooperation between India and Russia has emerged as a strategic pathway that goes beyond the traditional export of generic medicines. This partnership now encompasses joint production of active pharmaceutical ingredients (APIs), key intermediates, final drug formulations, and even regulatory alignment.
This approach represents a direct response to vulnerabilities in global supply chains and increasing trade restrictions—conditions that have pushed Russia toward diversifying import sources and encouraged India to expand stable and long-term export markets.
At the institutional level, pharmaceutical cooperation between the two countries has been elevated to formal and long-term frameworks. The signing of bilateral memoranda of understanding in pharmaceuticals and health has positioned the sector as a priority area in achieving the target of USD 100 billion in bilateral trade by 2030.
Currently, India has become the largest supplier of packaged pharmaceutical products in the Russian market. Despite global constraints, Indian pharmaceutical exports to Russia recorded moderate growth during 2023 and 2024.
From a technological perspective, the partnership is built on complementary strengths. India benefits from economies of scale in generic drug production and complex formulations, enabling cost-efficient and large-scale manufacturing.
Russia, in contrast, possesses strong capabilities in advanced chemistry and vaccine research and development. The combination of these strengths has facilitated the establishment of joint manufacturing facilities and technology transfer mechanisms.
The use of national currencies (ruble and rupee) in trade settlements has added stability to pharmaceutical exchanges, reducing exposure to currency volatility and international financial restrictions.
At the same time, multilateral cooperation within the BRICS framework—including the Virtual Vaccine Research and Development Center, operational since 2022—acts as a complementary platform, enabling knowledge exchange without the need for heavy bilateral investment.
Overall, the India–Russia pharmaceutical axis represents a practical reconfiguration of the global health supply chain. It strengthens national pharmaceutical security and offers a model for resilient, decentralized, and multipolar cooperation in the pharmaceutical industry.
In the coming years, this collaboration may contribute to lower drug costs in developing markets, improved access to essential medicines, and the consolidation of India and Russia as key players in the emerging architecture of global health.